Diferencia entre revisiones de «Terazosin»
(Created page with "==Administration== *Type: α-blocker *Dosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg *Routes of Administration: Oral *Common Trade Names: Hytrin ==Adult Dosing== ===Benign prostatic hyperplasia=== *1-10 mg PO qhs ===Hypertension=== *1-10 mg PO qhs ===Urolithiasis=== *Off-label: 2-5 mg PO qhs ==Pediatric Dosing== ''Safety/efficacy not established'' ==Special Populations== *Pregnancy Rating: C. weigh risk/benefit during pregnancy; n...") |
Sin resumen de edición |
||
| Línea 49: | Línea 49: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See [[Tamsulosin]]) | *α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See [[Tamsulosin]]) | ||
*Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension | *Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension | ||
**In a single-center European RCT, terazosin appears to be associated with a higher rate of symptomatic orthostatic hypotension<ref>de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.</ref> | **In a single-center European RCT, terazosin (vs tamsulosin) appears to be associated with a higher rate of symptomatic orthostatic hypotension<ref>de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.</ref> | ||
**In a meta-analysis from a Chinese team, more subjects receiving terazosin experienced dizziness and hypotension<ref>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.</ref> | **In a meta-analysis from a Chinese team, more subjects receiving terazosin (vs tamsulosin) experienced dizziness and hypotension<ref>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.</ref> | ||
==See Also== | ==See Also== | ||
Revisión actual - 03:21 1 oct 2023
Administration
- Type: α-blocker
- Dosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg
- Routes of Administration: Oral
- Common Trade Names: Hytrin
Adult Dosing
Benign prostatic hyperplasia
- 1-10 mg PO qhs
Hypertension
- 1-10 mg PO qhs
Urolithiasis
- Off-label: 2-5 mg PO qhs
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C. weigh risk/benefit during pregnancy; no human data available
- Lactation risk: Infant risk cannot be ruled out; weigh risk/benefit while breastfeeding
Renal Dosing
- Adult: No adjustment
Hepatic Dosing
- Adult: No adjustment
Contraindications
- Allergy to drug/class
Adverse Reactions
Serious
- Hypotension
- Syncope
- Priapism
Common
- Orthostatic hypotension
- Dizziness
- Headache
- Weakness
- Nausea
- Nasal Congestion
Pharmacology
- Half-life: 12-14 hrs
- Metabolism: CYP450
- Excretion: Feces (60%) and renal (40%)
Mechanism of Action
- α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See Tamsulosin)
- Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension
See Also
References
- ↑ de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.
- ↑ Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.